Detalhe da pesquisa
1.
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
Lancet Oncol
; 12(5): 431-40, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21507715